Pharming announces completion of enrollment in pediatric clinical trial of leniolisib - Pharming (NASDAQ:PHAR)

Benzinga

Center

High Factuality

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib - Pharming (NASDAQ:PHAR)

This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inh…